Adagrasib Demonstrates CNS Activity in KRAS G12C+ NSCLC
The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.
Checkpoint Blockade Drives Progress in Endometrial Cancer Treatment
An expert from NYU Langone outlines how checkpoint blockade approvals have helped advance endometrial cancer management.
Oncology Nurse Champion: Kathleen Lutz
From orchestrating local infusion appointments to making lunch for a patient, Kathleen Lutz, RN, NP-BC WH, constantly strives to provide an excellent level of supportive care.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
2 Clarke Drive Cranbury, NJ 08512